hotspot -WSS

hotspot

author：focus 2025-09-02 08:15:20 - browse：16589

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Medicare Advantage enrollment hits roughly 33.4 million

knowledge

WSS

Editas, Vertex strike deal on CRISPR

New study raises questions about niacin and heart health

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

SNAP should offer more nutrition education

Christmas in the PICU brings some surprising joy

Opioid cravings were reduced by anti

knowledge

hotspot

explore

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Bright Health sells Medicare Advantage business to Molina

Researchers tackle phage therapy hurdles for wider adoption

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Secretariat’s lessons for human medicine

At least 13 dead in Texas as scorching temps continue

Why health records don't always know when patients are dead

leisure time

How to keep neuroscience’s past racism from being its future

Editas, Vertex strike deal on CRISPR

Ukraine seeks to reclaim its role as a hub for clinical trials

Prime Medicine, Myeloid Therapeutics clash over genome

MD Anderson's Padmanee Sharma responds to research credit suit

Congress may force more Covid

focus

focus

knowledge

entertainment